Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, March 14th.
A number of other research firms have also recently weighed in on ALNY. Credit Suisse Group boosted their target price on shares of Alnylam Pharmaceuticals from $151.00 to $154.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 13th. B. Riley reduced their price objective on shares of Alnylam Pharmaceuticals from $205.00 to $200.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Jefferies Group set a $156.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 9th. Nomura upped their price objective on shares of Alnylam Pharmaceuticals to $86.00 and gave the company a “sell” rating in a report on Friday, February 9th. Finally, BMO Capital Markets dropped their price objective on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $134.15.
Shares of NASDAQ ALNY traded down $1.36 during mid-day trading on Wednesday, hitting $95.08. The company had a trading volume of 1,956,027 shares, compared to its average volume of 1,018,737. Alnylam Pharmaceuticals has a one year low of $47.16 and a one year high of $153.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23. The stock has a market capitalization of $10,246.53, a price-to-earnings ratio of -17.54 and a beta of 2.68.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The company had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same quarter last year, the business earned ($1.32) earnings per share. The company’s revenue was up 116.6% on a year-over-year basis. sell-side analysts expect that Alnylam Pharmaceuticals will post -6.88 EPS for the current year.
In other Alnylam Pharmaceuticals news, insider Akshay Vaishnaw sold 88,554 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $143.10, for a total value of $12,672,077.40. Following the completion of the transaction, the insider now directly owns 55,856 shares of the company’s stock, valued at $7,992,993.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Philip A. Sharp sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $129.00, for a total transaction of $1,935,000.00. Following the transaction, the director now directly owns 155,795 shares of the company’s stock, valued at $20,097,555. The disclosure for this sale can be found here. Insiders have sold 198,620 shares of company stock worth $28,404,143 in the last three months. 4.30% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Xact Kapitalforvaltning AB bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $1,819,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $4,384,000. Alkeon Capital Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $635,000. Macquarie Group Ltd. boosted its position in shares of Alnylam Pharmaceuticals by 214.5% during the fourth quarter. Macquarie Group Ltd. now owns 40,926 shares of the biopharmaceutical company’s stock worth $5,200,000 after acquiring an additional 27,914 shares during the last quarter. Finally, Vident Investment Advisory LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $262,000. Institutional investors own 92.28% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/bidaskclub-upgrades-alnylam-pharmaceuticals-alny-to-buy.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.